×
Skip to content
ShareCafe

  • Home
  • Shares
  • Advice
  • Wealth
    • Wealth Home
    • Product Profiles
  • Property
  • Video
  • Contributors
  • Community
  • About us
  • Facebook
  • Twitter
  • YouTube
  • RSS
Main Menu
Hayden Nicholson

Hayden Nicholson

Hayden Nicholson is an ETF/LIC Specialist at Bell Potter Securities. Hayden provides comprehensive coverage of the ETF and LIC sectors, producing a range of highly regarded reports covering investment fundamentals, asset class structure and cost, and the role of managed investments in portfolios.

Funds / LICs / Markets

Bell Potter LIC Weekly: WAM, Magellan

January 20, 2021January 20, 2021 - by Hayden Nicholson

Bell Potter analyst William Gormly updates developments in the LIC market.

Read More
Etfs

Bell Potter October ETF Report: Global Investment Styles Post COVID-19

November 30, 2020November 30, 2020 - by Hayden Nicholson

Bell Potter provides a summary of the ETF market in October and highlight both the Vanguard Global Value Equity Active ETF as well as the Montaka Global Extension Fund.

Read More
LICs

Bell Potter LIC Weekly: Sohn Hearts and Minds Investment Conference

November 24, 2020November 30, 2020 - by Hayden Nicholson

Bell Potter analyst Hayden Nicholson updates developments in the LIC market where in line with its investment strategy, Hearts and Minds Investments (HM1) are refreshing the conference portfolio.

Read More

Recently Added

  • Evening Report: Aussie shares lift despite light trading volumes
  • SXY – Macquarie rates the stock as Outperform
  • FPH – UBS rates the stock as Sell
  • Lunch Report: Market near 11-month high
  • Morning Report: ASX 200 set for modest gains despite mixed US stocks
  • DCN – Macquarie rates the stock as Underperform
  • PPT – Credit Suisse rates the stock as Outperform
  • BXB – Morgans rates the stock as Add

Subscribe to ShareCafe

The daily resource for hands-on investors. Market insights and investment ideas delivered free to your inbox.

Copyright 2020 Informed Investor Pty Ltd ABN 42 162 871 589. All rights reserved.
No portion of this website maybe reproduced, copied or in any way released without written permission.
Share Cafe is a Corporate Authorised Representative (001283561) of PacReef Asset Management Pty Ltd who holds an Australian Financial Services Licence (Number: 488045)

Terms of Service | Financial Services Guide | Privacy Policy | Contact | Advertise

DOWNLOAD RESEARCH REPORT

And a Door Opens Wide

Antisense Therapeutics’ lead drug sits at the nexus of two areas of drug development that are starting to grow dramatically in importance. One relates to its mode of action and the other to the type of drug it is. Combine that with management who know the drug very well and strong results in a trial in a horrible disease afflicting children, and you have the basis for true value creation.

SMSFBrokerFinancial AdviserRetail Investor

Please prove you are human by selecting the Key.


DOWNLOAD RESEARCH REPORT

Fit for tough times; prepared for coal’s upswing

Terracom has counter-cyclically placed itself in a position to improve efficiency and margins plus pursue organic mine growth. Cashflows will further swell once currently depressed coal prices rebound. These assets appear undervalued compared to our Base Case $0.27/share NPV valuation of TER. TER has upside on management’s record of delivering new projects from currently controlled development assets and/or by opportunistically securing acquisitions.

SMSFBrokerFinancial AdviserRetail Investor

Please prove you are human by selecting the Flag.

DOWNLOAD RESEARCH REPORT

A Laser-Like Focus on Adding Value

Since August 1st, Kazia Therapeutics has announced US Food & Drug Administration fast track status for one program & orphan drug and rare paediatric disease designation for another, while finishing the period by announcing a new trial for its cancer drug, paxalisib. Over the next nine months investors are likely to see six data readouts from five programs. How fast can a company go?

SMSFBrokerFinancial AdviserRetail Investor

Please prove you are human by selecting the House.